These cancers can be followed through urine cytologic examination which has proven quite successful in the surveillance and management of patients with previously treated bladder cancers [National Cancer Institute].
Diagnostic examination on biopsies performed in an outpatient setting (such as skin, cervical, bladder, GI, or non-rapid FNA). This service will be supported by customary immunohistochemistry and special stains. Timely and accurate diagnoses will be provided by an experienced Pathology staff and include CAP-approved reporting formats, interpersonal communication as needed, and established quality oversight.
Non-gynecologic cytology focused on urine cytology, both as screening for patients with higher risk or as follow-up to establish or treat bladder cancer:
1) Relevant exposures include chemical based such as: cigarette smoking; infection with bacteria, parasitic fungi, or viruses; and treatment with certain chemotherapeutic agents. A positive family history of bladder cancer has also been associated with an increased risk of bladder cancer.
2) Bladder cancer is the fourth most commonly diagnosed malignancy in men in the United States. It is estimated that 79,030 new cases of bladder cancer are expected to occur in the United States in 2017.
Dynix Diagnostix is an industry leading, full-service clinical laboratory. We deliver quality service and efficient results for molecular genetics, blood testing, toxicology, and pathology.
By admin Prohibitions against balance billing…
By: Jeff Cohen Healthcare professionals and…